Related Experiment Video
Updated: May 10, 2026
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Lessons learned from a highly-active CD22-specific chimeric antigen receptor
Adrienne H Long1, Waleed M Haso, Rimas J Orentas
1Pediatric Oncology Branch; National Cancer Institute; Center for Cancer Research; National Institutes of Health; Bethesda, MD USA.
Abstract:
CD22 is an attractive target for the development of immunotherapeutic approaches for the therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation chimeric antigen receptor (CAR) that targets CD22 holds significant therapeutic promise. The key aspect for the development of such a highly-active CAR was its ability to target a membrane-proximal epitope of CD22.
Insights
A novel chimeric antigen receptor (CAR) targeting CD22 shows promise for treating B-cell cancers. This CAR effectively targets a specific CD22 epitope, enhancing its therapeutic potential in immunotherapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- CD22 is a key target for B-cell malignancy immunotherapies.
- Chimeric antigen receptor (CAR) T-cell therapy offers a promising avenue for cancer treatment.
Purpose of the Study:
- To develop and evaluate a novel second-generation CAR targeting CD22.
- To assess the therapeutic potential of a CD22-targeting CAR for B-cell malignancies.
Main Methods:
- Engineering a second-generation CAR derived from the m971 antibody.
- Focusing CAR development on targeting a membrane-proximal CD22 epitope.
Main Results:
- The developed CAR demonstrates significant therapeutic promise.
- The CAR's efficacy is linked to its ability to target a specific CD22 epitope.
Conclusions:
- A CD22-targeting CAR, particularly one targeting a membrane-proximal epitope, is a viable immunotherapeutic strategy.
- This approach holds potential for treating B-cell malignancies.
